Zybio

Listed
Animal vaccines for swine, poultry, cattle, and pets are manufactured.

About Zybio

Zybio is a publicly listed company. Animal vaccines for swine, poultry, cattle, and pets are manufactured. It operates on a Direct-to-Consumer (D2C) and Reseller / Distribution model. The company has 277 employees. Zybio offers products and services including Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines. Its focus areas include Biotechnology and Animal Health. Its legal entity in India is Jilin Zybio Biological Products Co., Ltd (U99999MH1977PLC010754).

Company details

Animal vaccines are manufactured by Zybio, focusing on swine, poultry, cattle, sheep, and pets. Operations are based in Jilin City, China, with 14 GMP production lines. Products are exported to countries like Egypt, Pakistan, and Vietnam. Innovation is emphasized through research centers and laboratories for vaccine development. Recognition as a high-tech enterprise and multiple awards for industry contributions are received. The sector of animal health is primarily served with a focus on quality and technological advancement.

  • Employees 277
  • Stage Public
  • Sectors
    Healthcare
  • Website jlzybio.com
  • Legal Name Zhengye Biotechnology Holding Limited
Key Metrics
  • Annual Revenue
    $16.19 M (USD)
    -37.49
    as on Dec 31, 2025
  • Net Profit
    -$9.71 M (USD)
    -717.68
    as on Dec 31, 2025
  • EBITDA
    -$6.2 M (USD)
    -210.55
    as on Dec 31, 2025
  • Employee Count
    277

Products & Services of Zybio

Zybio offers a comprehensive portfolio of products and services, including Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines.

Swine Vaccines
Animal Health

Vaccines for swine are developed to prevent diseases.

Poultry Vaccines
Animal Health

Vaccines for poultry are produced to ensure protection.

Cattle and Sheep Vaccines
Animal Health

Vaccines for cattle and sheep prevent specific diseases.

Pet Vaccines
Animal Health

Vaccines for pets are designed for disease prevention.

IPO & Listings of Zybio

Zybio is a publicly listed company on the NASDAQ with ticker symbol ZYBT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date07 Jan 2025
  • Listed onNASDAQ: ZYBT
  • Listed entityZhengye Biotechnology Holding Limited
  • Exchange sectorHealth technology
  • ISINKYG989MS1016
  • Share price$1.48 (-12.43% on the day) · 2026-10-13
  • Market capitalisation$44.0M
  • Volume (last session)430,126

Financials of Zybio

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025$16.2M-$9.7M-$6.2M
2024$25.9M$1.6M$5.6M
2023$29.9M$4.4M$11.1M
2022$38.6M$6.9M$12.7M
2021$33.2M$6.0M$10.8M

Balance sheet, profit and loss, cash flow and ratios of , are on its company page.

Premium access

Detailed financial statements for Zybio

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Web traffic of Zybio

The website of Zybio (jlzybio.com) receives about 1K visits a month.

  • Monthly visits
    1K

    ▲ 5% vs previous month

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Zybio

Premium access

Complete news archive for Zybio

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Zybio

Zybio has 277 employees.

Annual revenue of Zybio is $16.19M as on Dec 31, 2025.

Animal vaccines are manufactured by Zybio, focusing on swine, poultry, cattle, sheep, and pets. Operations are based in Jilin City, China, with 14 GMP production lines. Products are exported to countries like Egypt, Pakistan, and Vietnam. Innovation is emphasized through research centers and laboratories for vaccine development. Recognition as a high-tech enterprise and multiple awards for industry contributions are received. The sector of animal health is primarily served with a focus on quality and technological advancement.

Zybio offers Swine Vaccines, Poultry Vaccines, Cattle and Sheep Vaccines, and Pet Vaccines.

Yes, Zybio is publicly traded on NASDAQ under the ticker symbol ZYBT.

Zybio operates through ,.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available